Australia's most trusted
source of pharma news
Posted 8 July 2024 AM
MSAC has branded a pricing proposal by Johnson & Johnson Innovative Medicine as 'unethical' - exposing the depth of bitterness in negotiations which have ended with the company's CAR T therapy for multiple myeloma, Carvykti, finally winning a recommendation.
The long-awaited good news for patients came hand-in-hand with a scathing rebuke from MSAC delivered in the 11-page Public Summary Document, which some are privately terming a "dummy spit" by the Committee, unhappy about the very public campaign which questioned why a recommendation was so slow coming.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.